Caleb Wegener1, Joshua Burns, Stefania Penkala. 1. Podiatry Program, School of Biomedical and Health Sciences, University of Western Sydney, Sydney, NSW, Australia. Caleb.Wegener@swahs.health.nsw.gov.au
Abstract
BACKGROUND: High injury rates observed in athletes with cavus feet are thought to be associated with elevated plantar pressure loading. Neutral-cushioned running shoes are often recommended to manage and prevent such injuries. PURPOSE: To investigate in-shoe plantar pressure loading and comfort during running in 2 popular neutral-cushioned running shoes recommended for athletes with cavus feet. STUDY DESIGN: Controlled laboratory study. METHODS:Plantar pressures were collected using the in-shoe Novel Pedar-X system during overground running in 22 athletes with cavus feet in 2neutral-cushioned running shoes (Asics Nimbus 6 and Brooks Glycerin 3) and a control condition (Dunlop Volley). Comfort was measured using a validated visual analog scale. RESULTS: Compared with the control, both neutral-cushioned running shoes significantly reduced peak pressure and pressure-time integrals by 17% to 33% (P < .001). The Brooks Glycerin most effectively reduced pressure beneath the whole foot and forefoot (P < .01), and the Asics Nimbus most effectively reduced rearfoot pressure (P <.01). Both neutral-cushioned running shoes reduced force at the forefoot by 6% and increased it at the midfoot by 12% to 17% (P < .05). Contact time and area increased in both neutral-cushioned running shoes (P < .01). The Asics Nimbus was the most comfortable, although both neutral-cushioned running shoes were significantly more comfortable than the control (P < .001). CONCLUSION: Two popular types of neutral-cushioned running shoes were effective at reducing plantar pressures in athletes with cavus feet. CLINICAL RELEVANCE: Regional differences in pressure reduction suggest neutral-cushioned running shoe recommendation should shift from being categorical in nature to being based on location of injury or elevated plantar pressure.
RCT Entities:
BACKGROUND: High injury rates observed in athletes with cavus feet are thought to be associated with elevated plantar pressure loading. Neutral-cushioned running shoes are often recommended to manage and prevent such injuries. PURPOSE: To investigate in-shoe plantar pressure loading and comfort during running in 2 popular neutral-cushioned running shoes recommended for athletes with cavus feet. STUDY DESIGN: Controlled laboratory study. METHODS: Plantar pressures were collected using the in-shoe Novel Pedar-X system during overground running in 22 athletes with cavus feet in 2 neutral-cushioned running shoes (Asics Nimbus 6 and Brooks Glycerin 3) and a control condition (Dunlop Volley). Comfort was measured using a validated visual analog scale. RESULTS: Compared with the control, both neutral-cushioned running shoes significantly reduced peak pressure and pressure-time integrals by 17% to 33% (P < .001). The Brooks Glycerin most effectively reduced pressure beneath the whole foot and forefoot (P < .01), and the Asics Nimbus most effectively reduced rearfoot pressure (P <.01). Both neutral-cushioned running shoes reduced force at the forefoot by 6% and increased it at the midfoot by 12% to 17% (P < .05). Contact time and area increased in both neutral-cushioned running shoes (P < .01). The Asics Nimbus was the most comfortable, although both neutral-cushioned running shoes were significantly more comfortable than the control (P < .001). CONCLUSION: Two popular types of neutral-cushioned running shoes were effective at reducing plantar pressures in athletes with cavus feet. CLINICAL RELEVANCE: Regional differences in pressure reduction suggest neutral-cushioned running shoe recommendation should shift from being categorical in nature to being based on location of injury or elevated plantar pressure.
Authors: Lourdes María Fernández-Seguín; Alberto Marcos Heredia-Rizo; Juan Antonio Díaz-Mancha; Paula González-García; Javier Ramos-Ortega; Pedro V Munuera-Martínez Journal: Medicine (Baltimore) Date: 2019-11 Impact factor: 1.817